Equities

Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1,918.50
  • Today's Change38.00 / 2.02%
  • Shares traded504.02k
  • 1 Year change+17.59%
  • Beta0.4175
Data delayed at least 20 minutes, as of Mar 28 2024 18:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments229292450
Total Receivables, Net873841876
Total Inventory891776695
Prepaid expenses727465
Other current assets, total35168.00
Total current assets2,1001,9992,094
Property, plant & equipment, net1,1411,0811,146
Goodwill, net388389285
Intangibles, net712735607
Long term investments655246
Note receivable - long term------
Other long term assets182311
Total assets4,6804,4714,372
LIABILITIES
Accounts payable309291262
Accrued expenses243171194
Notes payable/short-term debt467564
Current portion long-term debt/capital leases1157357
Other current liabilities, total626467439
Total current liabilities1,3391,0771,016
Total long term debt1,0301,135725
Total debt1,1911,283846
Deferred income tax251924
Minority interest111314
Other liabilities, total7792140
Total liabilities2,4822,3361,919
SHAREHOLDERS EQUITY
Common stock404042
Additional paid-in capital282282282
Retained earnings (accumulated deficit)2,1952,1292,353
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(319)(316)(224)
Total equity2,1982,1352,453
Total liabilities & shareholders' equity4,6804,4714,372
Total common shares outstanding221220231
Treasury shares - common primary issue131313
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.